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Abstract
Objective:  In this prospectively planned interim-analysis, the prevalence of chronic obstructive lung disease (COPD) phenotypes was determined
using magnetic resonance imaging (MRI) and X-ray computed tomography (CT) in non-small-cell-lung-cancer (NSCLC) patients.
Materials  and  methods:  Stage-III-NSCLC patients provided written informed consent for pulmonary function tests, imaging and the 6-min-
walk-test. Ventilation defect percent (VDP) and CT lung density (relative-of-CT-density-histogram <−950, RA950) were measured. Patients were
classified into three subgroups based on qualitative and quantitative COPD and tumour-specific imaging phenotypes: (1) tumour-specific ventilation
defects (TSD), (2) tumour-specific and other ventilation defects without emphysema (TSDV), and, (3) tumour-specific and other ventilation defects
with emphysema (TSDVE).
Results:  Seventeen stage-III NSCLC patients were evaluated (68 ±  7 years, 7 M/10 F, mean FEV1 = 77%pred) including seven current and 10
ex-smokers and eight patients with a prior lung disease diagnosis. There was a significant difference for smoking history (p  = .02) and FEV1/FVC
(p  = .04) for subgroups classified using quantitative imaging. Patient subgroups classified using qualitative imaging findings were significantly
different for emphysema (RA950, p  < .001). There were significant relationships for whole-lung VDP (p  < .05), but not RECIST or tumour-lobe
VDP measurements with pulmonary function and exercise measurements. Preliminary analysis for non-tumour burden ventilation abnormal-
ities using Reader-operator-characteristic (ROC) curves reflected a 94% classification rate for smoking pack-years, 93% for FEV1/FVC and
82% for RA950. ROC sensitivity/specificity/positive/negative likelihood ratios were also generated for pack-years, (0.92/0.80/4.6/0.3), FEV1/FVC
(0.92/0.80/4.6/0.3), RA950 (0.92/0.80/4.6/0.3) and RECIST (0.58/0.80/2.9/1.1).
Conclusions:  In this prospectively planned interim-analysis of a larger clinical trial, NSCLC patients were classified based on COPD imaging
phenotypes. A proof-of-concept evaluation showed that FEV1/FVC and smoking history identified NSCLC patients with ventilation abnormalities
appropriate for functional lung avoidance radiotherapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
The current standard of care for patients with non-small cell
lung cancer (NSCLC) relies on radiation therapy that focuses
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the radiation dose to the tumour, sparing healthy lung tissue.
However, the current standard approach for radiation therapy
planning uses four-dimensional computed tomography (4DCT)
to delineate the target volume and this does not take into account
lung function heterogeneity. This is an important consideration,
especially in ex-smokers with chronic obstructive pulmonary
disease (COPD) or other underlying lung disease. In these
patients, pulmonary functional imaging has been used to char-
acterize large functional deficits of poorly and unventilated lung
[1,2] which is typically very spatially heterogeneous. Moreover,
http://dx.doi.org/10.1016/j.ejro.2015.05.003
2352-0477/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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such functional defects cannot be easily predicted by smoking
history or other pulmonary function measurements, including
the forced expiratory volume in 1 second (FEV1) [1,3,4]. Ide-
ally, radiation treatment planning should derive improvements
from pulmonary imaging measurements that differentiate the
functioning from non-functioning lung, with attention focused
on the non-functioning part of the lung, independent of tumour
burden.
Pulmonary functional imaging methods such as single pho-
ton emission computed tomography (SPECT) [5,6], 4DCT [7,8]
and inhaled gas magnetic resonance imaging (MRI) [9,10], have
been previously incorporated in functional imaging lung avoid-
ance schemes, but this approach is not currently the standard
clinical practice. The feasibility of function-based intensity
modulated radiation therapy (IMRT) treatment planning [5,6,9],
has been demonstrated, in addition to measurements of lung
function before and after radiation treatment [7,11]. Impor-
tantly, when functional imaging was used to guide therapy
in radiation planning studies, dose reductions to functioning
lung were achievable [6,10]. Previous work also identified
that functional lung avoidance plans can be optimized in
patients with bullous lung disease and large perfusion defects
[12,13].
While these thoracic imaging techniques provide a way to dif-
ferentiate between functioning and non-functioning lung, there
are a number of inherent limitations that have restricted the
use of functional imaging for radiation therapy planning. For
example, with SPECT imaging, artefacts stemming from radi-
olabelled tracers are typically observed in the major airways
[14]. For 4DCT [15], lung function is indirectly measured over
a time series of breaths and the resultant lung function maps
require extensive image processing that is highly dependent on
deformable image registration [16,17]. Fourier-decomposition
4D MRI is an alternative imaging method that indirectly meas-
ures lung ventilation and perfusion and correlates well with
other pulmonary functional MR methods [18]. On the other
hand, hyperpolarized noble gas MRI, although very sensitive
to functional ventilation abnormalities, is limited because of its
reliance on specialized MRI and polarization equipment. While
the global quantities of 3He are very limited and expensive,
impeding its clinical uptake and translation, the sensitivity of this
method may guide the use of other MR methods (e.g. Fourier
decomposition, 129Xe MRI, etc.). In addition, although MRI
methods are well-tolerated, making them ideal for serial stud-
ies [19], until now, these methods have been limited to research
applications only.
Therefore, in an interim analysis of a larger clinical trial
[20], the objective of this proof-of-concept evaluation was
to quantify imaging phenotypes of COPD in patients with
NSCLC prior to concurrent chemo- and radiation therapy. We
aimed to determine the utility of conventional and clinically
available COPD measurements in stratifying patients for func-
tional lung avoidance radiotherapy. We hypothesized that COPD
phenotypes could be used to stratify NSCLC patients prior
to radiotherapy planning as a first step towards personalizing
treatment plans based on lung structural and functional mea-
surements.
2.  Materials  and  methods
2.1.  Study  participants
Study participants were evaluated in a prospectively planned
interim analysis of a clinical trial in over 60 patients [20].
The logistical details of this clinical trial (NCT02002052)
were previously published [20]; here we provide an interim
analysis of the feasibility of acquiring and quantifying MRI
phenotypes prior to randomization to standard or individual-
ized functional lung avoidance radiation treatment. Volunteers
with histologically confirmed non-resectable Stage IIIA or IIIB
NSCLC and a smoking history of >10 pack-years provided
written informed consent to this randomized controlled clini-
cal trial which complied with the Health Insurance Portability
and Accountability Act (HIPAA) and Personal Information Pro-
tection and Electronic Documents Act (PIPEDA), and approved
by our local research ethics board and by Health Canada. Briefly,
all subjects were required to be over 18 years of age, with
an Eastern Cooperative Oncology Group (ECOG) performance
score between 0 and 2, FEV1 > 30%pred, and able to undergo
platinum-based chemotherapy as determined by his/her treat-
ing physicians. Those subjects with contradictions to the MRI
(i.e. metal/electronic/magnetic implants, claustrophobia, etc.),
serious co-morbidities, prior thoracic radiation, metastatic dis-
ease, or conflicts with routine radiotherapy were not considered
suitable for the study. In addition to routine clinical care, in a
two and a half hour visit, all study volunteers underwent addi-
tional pulmonary function tests, MRI, one additional low dose
inspiratory CT, and the 6 min walk test (6MWT) [20].
2.2.  Pulmonary  function  tests
Spirometry was used to acquire the forced expiratory vol-
ume in one second (FEV1), forced vital capacity (FVC),
and FEV1/FVC according to American Thoracic Society
(ATS) guidelines (Medgraphics Elite Series Plethysmograph,
MedGraphics Corporation, St. Paul, MN, USA) [21]. Body
plethysmography was also performed to measure lung volumes
and the diffusing capacity of carbon monoxide (DLCO) was also
measured using the attached gas analyser (Medgraphics Elite
Series Plethysmograph).
2.3.  Image  acquisition
MRI was acquired in the coronal plane using a whole body
3.0 Tesla Discovery MR750 (General Electric Health Care,
Milwaukee, WI) system with broadband imaging capability.
Polarization of the 3He/129Xe gas was performed using a
polarizer system (HeliSpin/XeniSpin; Polarean, Durham,
NC, USA) and achieved polarization levels of approximately
40%/8%. Hyperpolarized 3He was diluted with medical-
grade N2 gas (Spectra Gases, NJ, USA) and 129Xe was
diluted with 4He/N2 and administered in 1.0-L Tedlar® bags
(Jensen Inert Products, FL, USA). Subjects were instructed
to inhale a gas mixture from the bag from functional residual
capacity (FRC) and image acquisition was performed under
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breath-hold conditions [22]. 1H MRI was acquired with subjects
in breath-hold using a whole-body radiofrequency coil and
a 1H fast spoiled gradient-recalled echo (FGRE) sequence
with a partial echo (16 s total data acquisition, repetition time
[TR]/echo time [TE]/flip angle = 4.7 ms/1.2 ms/30◦, field-of-
view [FOV] = 40 cm ×  40 cm, bandwidth [BW] = 24.4 kHz,
matrix = 128 ×  80, 15–17 slices, 15 mm slice thickness, 0 gap),
as previously described [22]. Hyperpolarized 3He MRI static
ventilation imaging was performed using a 2D multi-slice fast
gradient-recalled echo sequence with a partial echo (total data
acquisition time = 10 s; TR/TE/flip-angle = 3.8 ms/1.0 ms/7◦;
FOV = 40 cm ×  40 cm; matrix = 128 × 80; BW = 62.50 kHz;
number of excitations [NEX] = 1; number of slices = 16; slice
thickness = 15 mm) during breath hold [22]. Hyperpolarized
129Xe MRI static ventilation imaging was performed to
determine whether it provided similar or additional information
to 3He MRI. 129Xe MRI was performed using a 3D FGRE
sequence (total data acquisition time = 16 s; TR/TE/flip-
angle = 7.0 ms/1.8 ms/variable; FOV = 40 cm ×  40 cm; matrix =
128 ×  128; BW = 9 kHz; NEX = 1; number of slices = 16; slice
thickness = 15 mm) during a breath-hold. The time duration
between 3He and 129Xe was 10–15 min. The subject was
removed from the bore of the MRI to allow for the coils to be
switched. The subject was re-localized, 1H MRI was performed
followed by 129Xe MRI.
Thoracic CT images were acquired at FRC + 1 L using
a multi-detector, 64-slice Lightspeed VCT scanner (General
Electric Health Care, Milwaukee, WI) (64 mm ×  0.625 mm
collimation, 120 kVp, 100 effective mA, tube rotation
time = 500 ms, pitch = 1.0) [23]. A spiral acquisition was used
and images reconstructed using a standard convolution kernel
to 1.25 mm [23].
2.4.  Image  analysis
Noble gas static ventilation images were segmented and reg-
istered to the 1H MRI thoracic cavity using custom software
we previously generated using MATLAB R2014a (Mathworks,
Natrick, MA, USA), as previously described [24]. Ventilation
abnormalities were quantified using the ventilation defect per-
cent (VDP) which represents the volume of ventilation defects
(VDV) normalized to the thoracic cavity volume (TCV). Briefly,
3He static ventilation images were segmented by a single
observer (K.S. with three years of experience performing semi-
automated segmentation and a coefficient of variation of 4%)
using a k-means approach that classified voxel intensity val-
ues into five clusters ranging from signal void (cluster 1[C1]
or VDV) and hypo-intense (cluster 2 [C2]) to hyper-intense
signal (cluster 5 [C5]), therefore, generating a gas distribution
cluster-map. For delineation of the ventilation defect bound-
aries, a seeded region-growing algorithm was used to segment
the 1H MRI thoracic cavity for registration to the cluster-map,
as previously described [24].
Pulmonary Workstation 2.0 (VIDA Diagnostics Inc.,
Coralville, IA, USA) was used to quantify the relative area of
the CT density histogram with attenuation values <−950 HU
(RA950) as well as segmenting the lungs and lobes. Using the
pulmonary lobe masks produced by VIDA, the VDP for each
pulmonary lobe was determined by applying these masks to the
static ventilation images. Ventilation defect percent was calcu-
lated for the tumour lobe(s) (VDPTL) and the lobes with no
tumour (VDPNTL). VDPTL was generated by normalizing the
ventilation defect volume for a specific lobe to the corresponding
lobe volume. Similarly, the VDPNTL was generating by normal-
izing the ventilation abnormalities of the non-tumour lobe(s)
to the corresponding lobar volume(s). Finally, the Response
Evaluation Criteria in Solid Tumours (RECIST) was evaluated
[25].
Subjects were classified into three sub-groups based on qual-
itative and quantitative imaging evidence of ventilation defects
and emphysema: (1) subjects with tumour-specific ventilation
defects (TSD), (2) subjects with tumour-specific and other venti-
lation defects with no emphysema (TSDV), and, (3) subjects with
tumour-specific and other ventilation defects with emphysema
(TSDVE). Three observers ((a) G.P. with 10 years of experience,
(b) K.S. with three years of experience, and (c) D.P.I.C. with
two years of experience analyzing noble gas MRI and CT) in
a consensus decision, qualitatively evaluated and classified all
subjects based on the visible evidence of tumour and non-tumour
lobe ventilation defects and on the presence of emphysema. For
qualitative analyses, all image slices were evaluated using 3D
Slicer 4.2 open-source platform (http://www.slicer.org, Boston,
MA) as the visualization environment and with flexible win-
dows and levels for ventilation and emphysema extent. For
quantitative classification of subjects, the upper limit of the
95% confidence interval of VDP measurements from a pre-
viously published [26] study in healthy volunteers was used
as the threshold (>3%) for ventilation defects. Subjects with
ventilation defects in the tumour lobe only (non-tumour lobes:
VDP < 3%) were classified in the TSD subgroup. Subjects with
ventilation defects in non-tumour lobes (VDP > 3%) were classi-
fied in the TSDV subgroup. For those subjects with non-tumour
lobe ventilation defects, the value of RA950 ≥  5% was used
to further stratify these subjects into the TSDVE subgroup
[27].
2.5.  Statistical  analysis
A one-way analysis of variance (ANOVA) with post hoc
Tukey HSD (Honest Significant Differences) and Pearson cor-
relation coefficients (r) were used to determine the relationships
between measurements using SPSS Statistics V22.0 (SPSS Inc.,
IBM Corporation, Armonk, NY, USA). Results were consid-
ered significant when the probability of two-tailed type I error
() was less than 5% (p  < .05). Receiver-operating characteris-
tic (ROC) curves were used to characterize the performance
of pulmonary function test and other clinical measures as
predictors of the presence of ventilation defects not asso-
ciated with tumour burden (control group: TSD sub-group;
patient group: TSDV and TSDVE sub-groups). The maximum
Youden’s J index value (J = sensitivity + specificity-1) was used
to determine the optimum cut-off point and the corresponding
sensitivity, specificity, positive and negative likelihood ratios
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Fig. 1. 3He MRI and CT for representative subjects with tumour-specific ventilation defects (TSD), tumour-specific and other ventilation defects (TSDV), without
emphysema, and tumour-specific and other ventilation defects with emphysema (TSDVE) based on quantitative analysis. Left: 3He MRI coronal static ventilation in
blue co-registered to 1H MRI. Middle: CT density masks where yellow = attenuation < −950 Hounsfield units (RA950). Right: CT three-dimensional low-attenuation
clusters (LAC), represented as spheres with CT densitometry values <−950 HU and CT three-dimensional reconstruction airway tree. Yellow arrows indicate tumour
location. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
were calculated. It should be noted that to demonstrate a sig-
nificant Reader Operator curve result with the same number
of positive and negative cases, the required sample size is
26 [28]. The ROC analysis statistics were performed using
GraphPad Prism version 6.02 (GraphPad, Inc., San Diego, CA,
USA).
3.  Results
3.1.  Participants
Twenty-three subjects consented to the study, but only 17
completed MRI and pulmonary function tests (PFTs) and were
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Table 1
Subject listing and classification.
Sex Age (y) Pack-years Current smoker Tumour
location
Previously diagnosed
lung disease
Quantitative
classification
Qualitative classification
001 F 62 50 N RLL COPD TSDVE TSDVE
002 F 69 50 N LLL COPD TSDVE TSDVE
003 M 67 50 N RUL None TSDV TSDV
004 F 68 35 N RUL COPD TSD TSDV
006 M 71 50 Y LUL COPD TSDVE TSDVE
007 F 63 50 Y RUL None TSDV TSDV
008 F 70 45 Y RUL None TSD TSD
010 F 65 35 N RML None TSDV TSDV
011 F 56 42 Y LLL COPD TSDV TSDV
012 M 72 50 N LLL COPD TSDVE TSDVE
013 F 62 10 N RUL None TSD TSDV
015 F 79 30 Y LLL None TSD TSDV
017 F 67 30 N RUL Asthma TSD TSDV
019 M 68 53 Y RUL None TSDV TSDV
020 M 59 40 N RML None TSDVE TSDVE
021 M 81 70 N LUL None TSDV TSDV
023 M 74 90 Y LUL COPD TSDV TSDV
Mean 7 M/10 F 68 46 7 Y/10 N 7 COPD/
1 Asthma/
9 none
5 TSD/
7 TSDV/
5 TSDVE
1 TSD/11 TSDV/5 TSDVE
RLL = right lower lobe; RUL = right upper lobe; RML = right middle lobe; LLL = left lower lobe; LUL = left upper lobe; TSD = tumour-specific ventilation defects
only; TSDV = tumour-specific and other ventilation defects with no emphysema; TSDVE = tumour-specific and other ventilation defects with emphysema.
included in this analysis. The six subjects who consented but
did not complete evaluations were unable to participate because
of difficulties in travel conditions to the site (snowstorm).
Table 1 shows a subject listing for the 17 subjects (68 ±  7 years,
7 M/10 F) who completed baseline imaging and pulmonary func-
tion measurements and participant classification according to
both qualitative and quantitative imaging phenotypes. All sub-
jects were diagnosed with locally advanced Stage IIIA or IIIB
NSCLC according to the American Joint Committee on Can-
cer (7th edition) [29] with a smoking history of >10 pack-years
(46 ±  17 pack-years). Of the 17 subjects who completed base-
line measurements, seven were current smokers and ten were
ex-smokers with a mean years-quit of 16 ±  13 years. Eight sub-
jects had a prior diagnosis of lung disease. Nine patients reported
FEV1/FVC < 70% and four patients reported FEV1 < 50%pred.
3.2.  Imaging  and  other  measurements  by  subgroup
Fig. 1 shows the coronal 3He static ventilation image with the
corresponding RA950 map, CT low attenuation cluster (LAC)
map and the airway tree for six representative subjects, includ-
ing: (1) S4 and S17 with quantitative tumour-specific ventilation
defects only, (2) S3 and S19 with quantitative tumour-specific
and other ventilation defects, and, (3) S2 and S6 with quantita-
tive tumour-specific and other ventilation defects with comorbid
emphysema. Yellow arrows show the location of tumour masses.
Specifically, subjects S4 and S17 in the TSD subgroup showed
homogeneous regions of ventilation, except for the regions
near the tumour, where obvious ventilation abnormalities were
clearly visible. Qualitatively, these two subjects also showed
more complete airway trees than those subjects in the TSDV and
TSDVE subgroup. Subjects in the TSDV and TSDVE subgroups
had numerous and large ventilation defects related to the tumour
and also in non-tumour regions of interest. For the two repre-
sentative participants (S2 and S6) in the TSDVE subgroup there
was visible evidence of significant centrilobular emphysema as
reflected in the RA950 and low attenuating cluster maps.
Table 2 shows subject demographics, pulmonary function
and 6MWT measurements for all participants and the three
qualitative and quantitative comparator subgroups. There were
no significant differences among the qualitatively determined
subgroups, except for RA950 (p  < .001). In the quantitatively
determined subgroups, there were significant differences for
FEV1/FVC (p  = .04) and smoking history (p  = .02). Post hoc
analysis showed that the TSDV subgroup had significantly dif-
ferent FEV1/FVC (p  = .04), and smoking history (p  = .02) than
the TSD subgroup.
3.3.  Univariate  relationships
As shown in Table 3 for all measurements and in detail in
Fig. 2, there were significant relationships for whole lung VDP
with pulmonary function (FEV1, FEV1/FVC, IC, and FRC),
DLCO, 6MWD, and pre-6MWT oxygen saturation measure-
ments but not RECIST or RA950 measurements. For tumour-lobe
VDP, there was a significant relationship with pre-6MWT SpO2
while for non-tumour-lobe VDP there was a significant rela-
tionship with pulmonary function measurements (FEV1/FVC
and FRC). Finally, RA950 was significantly related to FRC
and the longest tumour diameter RECIST measurement was
significantly related to VDPTL. Fig. 2 shows the significant
relationships for VDP with SpO2, VDPNTL with FRC and
FEV1/FVC and finally RA950 with FRC.
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Table 2
Subject demographics, pulmonary function test, and imaging measurements.
Mean (±SD) All Quantitative classification Qualitative classification
(n = 17) TSD TSDV TSDVE p-value TSD TSDV TSDVE p-value
(n = 5) (n = 7) (n = 5) (n = 1) (n = 11) (n = 5)
Age yrs 68 (7) 69 (6) 68 (8) 67 (6) .9 70 68 (7) 67 (6) .9
Male n 7 0 4 3 – 0 4 3 –
BMI kg/m2 28 (4) 27 (4) 29 (4) 28 (6) .8 25 28 (4) 28 (6) .8
Pack years 46 (17) 30 (13) 56 (19) 48 (4) .02 45 45 (22) 48 (4) ∼1
Lung disease n 8 2 2 4 – 0 4 4 –
RECIST mm 49 (22) 54 (21) 40 (25) 57 (18) .4 90 42 (20) 57 (18) .07
FEV1%pred 77 (28) 94 (14) 68 (27) 72 (36) .3 77 79 (26) 72 (36) .9
FEV1/FVC % 65 (10) 75 (3) 61 (8) 62 (13) .04 71 66 (10) 62 (13) .7
IC %pred 86 (22) 100 (20) 83 (21) 76 (22) .2 113 88 (21) 76 (22) .3
FRC %pred 116 (27) 97 (10) 117 (27) 134 (30) .08 105 109 (24) 134 (30) .2
DLCO %pred 55 (18) 57 (20) 60 (13) 45 (22) .4 46 60 (16) 45 (22) .3
SpO2% 95 (5) 98 (2) 95 (5) 91 (8) .2 98 96 (4) 91 (8) .2
6MWD m 355 (77) 372 (78) 360 (47) 331 (115) .7 313 370 (59) 331 (115) .6
VDP % 13 (10) 7 (4) 13 (11) 20 (9) – 13 10 (10) 19 (9) .3
VDPTL % 26 (24) 23 (25) 17 (13) 41 (32) – 60 16 (14) 41 (32) .05
VDPNTL % 8 (9) 1 (1) 10 (12) 12 (8) – 1 7 (10) 12 (8) .5
RA950% 4 (4) 1 (1) 1 (1) 9 (3) – 1 1 (1) 9 (3) <.001
Bold values represent significant differences.
TSD = tumour-specific ventilation defects only; TSDV = tumour-specific and other ventilation defects with no emphysema; TSDVE = tumour-specific and other
ventilation defects with emphysema; Sig Dif = Significant difference between subgroups (p < .05) determined by ANOVA; SD = standard deviation; %pred = percent
predicted; BMI = body mass index; Lung disease = previously diagnosed lung disease; RECIST = Response Evaluation Criteria in Solid Tumours baseline longest
diameter; FEV1 = forced expiratory in 1 s; FVC = forced vital capacity; IC = inspiratory capacity; FRC = functional residual capacity; DLCO = diffusing capacity
of carbon monoxide; SpO2 = pre-6MWT digital oxygen saturation value 6MWT = 6 min walk test; 6MWD = distance travelled in 6 min; VDP = ventilation defect
percent; TL = tumour lobe; NTL = non-tumour lobes; RA950 = relative area of the lung with attenuation values <−950 HU.
Table 3
Univariate relationships between imaging measurements and pulmonary function, smoking history, and 6MWT measurements.
VDPr (p-value) VDPNTLr (p-value) VDPTLr (p-value) RA950r (p-value) RECISTr (p-value)
FEV1%pred −0.58 (.02) −0.47 (.06) −0.25 (.3) −0.06 (.8) −0.10 (.7)
FEV1/FVC % −0.51 (.04) −0.73 (.001) −0.07 (.8) −0.33 (.2) −0.12 (.7)
IC %pred −0.64 (.01) −0.45 (.07) −0.30 (.3) −0.17 (.2) −0.03 (.9)
FRC %pred 0.51 (.04) 0.74 (.001) 0.19 (.5) 0.50 (.04) 0.003 (.9)
DLCO %pred −0.54 (.03) −0.11 (.7) −0.46 (.06) −0.28 (.3) −0.27 (.3)
SpO2% −0.71 (.001) −0.34 (.2) −0.56 (.02) −0.30 (.3) −0.32 (.2)
6MWD m −0.50 (.04) −0.05 (.8) −0.48 (.05) −0.07 (.8) −0.18 (.5)
Pack−years yr 0.34 (.2) 0.25 (.3) 0.13 (.6) 0.16 (.5) 0.29 (.3)
VDPTL % 0.59 (.01) 0.16 (.5) – 0.10 (.7) 0.53 (.03)
Bold values represent significant correlations.
VDP = ventilation defect percent; NTL = non-tumour lobes; TL = tumour lobe; RA950 = relative area of the lung with attenuation values <−950 HU;
RECIST = Response Evaluation Criteria in Solid Tumour longest diameter; SpO2 = pre-6MWT digital oxygen saturation value; 6MWD = 6 min walk distance.
3.4.  ROC  analysis
In Fig. 3, we evaluated a number of different measure-
ments as discriminants of patients with and without ventilation
abnormalities beyond the tumour region-of-interest using ROC
curves. FEV1/FVC and pack-years were evaluated because
these two measurements were significantly different for the
quantitatively determined subgroups. RA950 was also evalu-
ated in order to ascertain the role of underlying emphysema
in discriminating patients. Tumour RECIST measurements
were also evaluated because these measurements are com-
monly used to reflect tumour burden. Pack-years (AUC = 0.94,
95% CI = 0.83–1.06, p  = .005), FEV1/FVC (AUC = 0.93, 95%
CI = 0.82–1.05, p = .006) and RA950 (AUC = 0.82, 95%
CI = 0.58–1.06, p  = .04) significantly discriminated NSCLC
patients with additional non-tumour specific ventilation defects,
but RECIST measurements (AUC = 0.60, 95% CI = 0.32–0.88,
p = .5) did not. Furthermore, for each diagnostic measurement,
the established cut-off point and the corresponding performance
characteristics (sensitivity, specificity, positive and negative like-
lihood ratios) were: pack-years: >37.5 years, 0.92, 0.80, 4.6, 0.3;
FEV1/FVC: <73.5%, 0.92, 0.80, 4.6, 0.3; RA950: >1.15%, 0.92,
0.80, 4.6, 0.3; RECIST: <45.5 mm, 0.58, 0.8, 2.9, 1.1.
4.  Discussion
To better understand the feasibility of pulmonary imaging
structure–function phenotyping of patients prior to radiation
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Fig. 2. Univariate relationships for imaging measurements and other measurements. (A) VDP and SpO2 (r = −0.71, p = .001), (B) VDPNTL and FEV1/FVC (r = −0.73,
p = .001), (C) VDPNTL and FRC (r = 0.74, p = .001), and, (D) RA950 and FRC (r = 0.50, p = .04). The dotted lines represent the 95th confidence interval of the regression
lines.
Fig. 3. Receiver-operating characteristic curves for the identification of ventila-
tion defects not associated with the tumour using pack-years (black solid line),
FEV1/FVC, (dark grey solid line), RA950, (black dashed line), and RECIST
longest diameter (dark grey dashed line). The area under the curve, [95%
confidence interval], (p-value) were: pack-years = 0.94, [0.83–1.06] (p = .005);
FEV1/FVC = 0.93 [0.82–1.05], (p = .006); RA950 = 0.82, [0.58–1.05], (p = .04),
and; RECIST = 0.60, [0.32–0.88], (p = .5).
therapy planning, we evaluated 17 Stage III NSCLC subjects
based on regional ventilation heterogeneity and emphysema
measurements before their radiation therapy plans were for-
mulated. We made a number of observations including: (1)
three different subgroups were quantitatively and qualitatively
identified based on the presence of tumour-specific ventilation
abnormalities, and COPD-biomarkers such as non-tumour ven-
tilation abnormalities and emphysema, (2) for quantitatively
identified subgroups, there were significant differences for pack-
years and FEV1/FVC, but not tumour RECIST measurements,
and for qualitatively identified subgroups, there was a significant
RA950 difference, (3) whole lung and non-tumour lobe VDP
were significantly correlated with pulmonary function test mea-
surements, but tumour lobe VDP and RECIST measurements
were not, and, (4) ROC analysis identified smoking pack-years,
FEV1/FVC, and RA950 as diagnostics for non-tumour burden
imaging findings reflective of COPD.
We used quantitative pulmonary imaging to classify patients
based on the extent of underlying COPD and independent of
pulmonary function tests. Three different subgroups were iden-
tified and it was somewhat unexpected that not all NSCLC
patients with a previous diagnosis of asthma or COPD exhib-
ited the ventilation heterogeneity commonly observed in COPD
subjects [1,2]. The premise of functional lung avoidance radia-
tion therapy is the specific targeting of regional non-functioning
lung, so subjects with no ventilation heterogeneity would not
be good candidates for this approach, as previously described
using SPECT perfusion imaging [13]. This finding has had a
profound effect on our original plan to randomize all NSCLC
patients to either standard or individualized radiation therapy
planning because only a subgroup of patients exhibited COPD
phenotypes such as ventilation heterogeneity and emphysema
that could be used in the radiation treatment planning process.
We also evaluated the practicality of using qualitative  imag-
ing phenotypes of COPD and noted that the composition of the
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three subgroups was markedly different with respect to patients
with tumour-specific and other defects. These results can be
explained by the semi-automated segmentation tool used for
quantitative analysis of noble gas MRI ventilation. As previ-
ously described [24], an expert observer can distinguish between
four visually different classes of 3He MRI gas signal includ-
ing: signal void, hypointense regions, normal intensity, and
hyperintense signal [24]. Quantitative segmentation depends on
k-means clustering that identifies two distinct clusters (signal
void and hypointense clusters), but visually, these regions appear
as signal void. Therefore patients with visibly obvious ventila-
tion defects may not meet the threshold for ventilation defect
percent. This is evident by the fact that there were more sub-
jects with qualitatively as compared to quantitatively identified
ventilation defects. Regardless, for the two different types of
subgroups, there were no significant differences observed for
pulmonary function, 6 min walk test or MRI measurements,
although emphysema (RA950) was significantly different. These
results lead us to believe that ventilation defects may be due to
a combination of small airway occlusion, mucous plugs, airway
wall thickening and inflammation or bullous disease, which are
common in COPD [30,31]. These results also suggest that qual-
itative analysis may not be appropriate for phenotyping COPD
patients, supporting the need for quantitative analysis or the use
of novel biomarkers [32] not investigated here.
It is interesting to note that whole lung and non-tumour lobe
VDP were significantly correlated with pulmonary function test
measurements, but baseline RECIST measurements and VDPTL
did not. These results are consistent with previous findings which
reported a relationship for increased hyperpolarized gas MRI
ventilation heterogeneity with poor lung function and exercise
capacity in COPD [1,33]. To determine if the diminished pul-
monary function observed in these subjects was due to tumour
burden or the underlying COPD, we determined the relation-
ships for VDP in the tumour lobe and non-tumour lobes. The
fact that VDP in the non-tumour lobes was related to pulmonary
function test measurements reinforces the notion that tumour
burden alone does not explain airflow and exercise limitation in
NSCLC subjects.
Finally, among the three quantitatively identified subgroups,
there were significant differences for smoking history (pack-
years) and FEV1/FVC, but not for exercise capacity or tumour
RECIST measurements. This supports the idea that the air-
flow limitation observed in NSCLC patients is contributed
by a combination of the tumour burden, airways disease and
emphysema, similar to what was previously observed in COPD
subjects [1,34]. Importantly, ROC analysis estimated a classi-
fication rate of 94% for pack-years and 93% for FEV1/FVC
when discriminating patients based on COPD imaging phen-
otypes. Smoking history measured in pack-years, as well as
FEV1/FVC, and RA950 showed 92% sensitivity (true posi-
tives) and 80% specificity (true negatives). The likelihood
ratios for these diagnostic measurements also suggested that
NSCLC patients with a positive test (i.e. pack-years > 37.5 years,
FEV1/FVC < 73.5%, RA950 > 1.15%) were approximately five
times more likely to have COPD-like ventilation abnormalities
as NSCLC patients with a negative test (i.e. pack-years < 37.5
years, FEV1/FVC > 73.5%, RA950 < 1.15%). This strongly sug-
gests that FEV1/FVC, pack-years, and RA950 can be used
as diagnostics for COPD-related ventilation abnormalities in
patients with NSCLC. Although these measures had similar
sensitivity and specificity, the AUC suggested different clas-
sification rates for FEV1/FVC and pack-years (classification
rates of 93% and 94%, respectively) versus RA950 (classifica-
tion rate of 82%). We also acknowledge that the sample size for
the interim ROC analysis was smaller than typically required to
determine significant predictors, so caution must be used in its
interpretation and the results should be considered exploratory
and hypothesis generating. Certainly, once the clinical trial is
completed, 64 subjects will be evaluated and the results of the
interim analysis will help guide recruitment to appropriately test
our hypotheses.
We recognize that because of the expense and limited quan-
tities of 3He gas, alternative pulmonary imaging methods such
as 129Xe MRI and Fourier decomposition MRI should be opti-
mized and utilized to provide similar lung structure–function
COPD measurements. It is also important to note that these
subjects were classified based on the presence of ventilation
defects and emphysema without regard to the location of the
tumour with respect to the ventilation defects and emphyse-
matous regions. Unfortunately, due to the small sample size in
this study, categorizing these subjects based on tumour location
was not feasible. Future work should incorporate this informa-
tion when phenotyping subjects for functional lung avoidance
radiation therapy.
5.  Conclusions
In summary, we classified NSCLC subjects into three
subgroups based on imaging measurements of ventilation
heterogeneity and the presence of emphysema. In this proof-
of-concept analysis, pulmonary imaging was used to phenotype
NSCLC patients on the basis of underlying COPD biomarkers of
airways disease and emphysema. We observed that non-tumour
lobe ventilation heterogeneity was related to pulmonary func-
tion test measurements. In addition, smoking history and airflow
limitation independently provided a >93% classification rate
for patients with ventilation abnormalities beyond the tumour
suggesting that these measurements may be used to categorize
NSCLC patients for functional lung avoidance radiation therapy
schemes. Taken together these results suggest that COPD phen-
otypes provide a way to identify NSCLC patients for functional
lung avoidance radiation therapy.
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